118 related articles for article (PubMed ID: 10803408)
1. mdm2 mRNA level is a prognostic factor in soft tissue sarcoma.
Taubert H; Koehler T; Meye A; Bartel F; Lautenschläger C; Borchert S; Bache M; Schmidt H; Würl P
Mol Med; 2000 Jan; 6(1):50-9. PubMed ID: 10803408
[TBL] [Abstract][Full Text] [Related]
2. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities.
Würl P; Meye A; Schmidt H; Lautenschläger C; Kalthoff H; Rath FW; Taubert H
Oncogene; 1998 Mar; 16(9):1183-5. PubMed ID: 9528860
[TBL] [Abstract][Full Text] [Related]
3. High bad and bcl-xL gene expression and combined bad, bcl-xL, bax and bcl-2 mRNA levels: molecular predictors for survival of stage 2 soft tissue sarcoma patients.
Köhler T; Würl P; Meye A; Lautenschläger C; Bartel F; Borchert S; Bache M; Schmidt H; Holzhausen HJ; Taubert H
Anticancer Res; 2002; 22(3):1553-9. PubMed ID: 12168836
[TBL] [Abstract][Full Text] [Related]
4. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
5. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer.
Ko JL; Cheng YW; Chang SL; Su JM; Chen CY; Lee H
Int J Cancer; 2000 May; 89(3):265-70. PubMed ID: 10861503
[TBL] [Abstract][Full Text] [Related]
6. Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis.
Bartel F; Schulz J; Böhnke A; Blümke K; Kappler M; Bache M; Schmidt H; Würl P; Taubert H; Hauptmann S
Int J Cancer; 2005 Nov; 117(3):469-75. PubMed ID: 15906355
[TBL] [Abstract][Full Text] [Related]
7. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma.
Bartel F; Meye A; Würl P; Kappler M; Bache M; Lautenschläger C; Grünbaum U; Schmidt H; Taubert H
Int J Cancer; 2001 May; 95(3):168-75. PubMed ID: 11307150
[TBL] [Abstract][Full Text] [Related]
8. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O
J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888
[TBL] [Abstract][Full Text] [Related]
9. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction.
Miyajima K; Tamiya S; Oda Y; Adachi T; Konomoto T; Toyoshiba H; Masuda K; Tsuneyoshi M
Cancer Lett; 2001 Mar; 164(2):177-88. PubMed ID: 11179833
[TBL] [Abstract][Full Text] [Related]
10. RT-PCR amplification of RNA extracted from formalin-fixed, paraffin-embedded oral cancer sections: analysis of p53 pathway.
Tachibana M; Shinagawa Y; Kawamata H; Omotehara F; Horiuchi H; Ohkura Y; Kubota K; Imai Y; Fujibayashi T; Fujimori T
Anticancer Res; 2003; 23(3C):2891-6. PubMed ID: 12926130
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of deletion-mutant epidermal growth factor receptor is associated with altered genotoxic stress-provoked p53 mRNA induction in a human glioblastoma cell line.
Halatsch ME; Schmidt U; Bötefür IC; Holland JF; Ohnuma T
Anticancer Res; 2001; 21(1A):189-95. PubMed ID: 11299733
[TBL] [Abstract][Full Text] [Related]
12. Elevated transcript levels from the MDM2 P1 promoter and low p53 transcript levels are associated with poor prognosis in human pancreatic ductal adenocarcinoma.
Grochola LF; Taubert H; Greither T; Bhanot U; Udelnow A; Würl P
Pancreas; 2011 Mar; 40(2):265-70. PubMed ID: 21404460
[TBL] [Abstract][Full Text] [Related]
13. Growth reduction of a xenotransplanted human soft tissue sarcoma by MDM2 antisense therapy via implanted osmotic minipumps.
Würl P; Bartel F; Meye A; Kappler M; Bache M; Schmidt H; Schönfelder M; Taubert H
Int J Oncol; 2002 May; 20(5):1087-93. PubMed ID: 11956608
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity at 12q14-15 often occurs in stage I soft tissue sarcomas and is associated with MDM2 amplification in tumors at various stages.
Taubert H; Schuster K; Brinck U; Bartel F; Kappler M; Lautenschläger C; Bache M; Trump C; Schmidt H; Holzhausen HJ; Würl P; Schlott T
Mod Pathol; 2003 Nov; 16(11):1109-16. PubMed ID: 14614050
[TBL] [Abstract][Full Text] [Related]
16. Competitive reverse transcription/polymerase chain reaction for the quantification of p53 and mdm2 mRNA expression.
Totzke G; Sachinidis A; Vetter H; Ko Y
Mol Cell Probes; 1996 Dec; 10(6):427-33. PubMed ID: 9025080
[TBL] [Abstract][Full Text] [Related]
17. [HDMX amplification and high levels of HDMX-S splice variant are correlated with a poor prognosis in soft tissue sarcomas].
Bartel F; Schulz J; Blümke K; Kappler M; Bache M; Schmidt H; Taubert H
Verh Dtsch Ges Pathol; 2004; 88():199-206. PubMed ID: 16892553
[TBL] [Abstract][Full Text] [Related]
18. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
19. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor and insulin-like growth factor-I receptor expression and function in human soft-tissue sarcoma cells.
Beech D; Pollock RE; Tsan R; Radinsky R
Int J Oncol; 1998 Feb; 12(2):329-36. PubMed ID: 9458358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
